TD139, a 3,3’-bis-(4-aryltriazol-1-yl) thiodigalactoside has been considered as the most advanced small-molecule galectin-3 inhibitor and is now in clinical trials for idiopathic pulmonary fibrosis (IPF) [33]. This evidence concerns the gene LGALS3 and idiopathic pulmonary fibrosis.